T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells
Autologous cell immunotherapy using B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cells is an effective novel treatment for multiple myeloma (MM). This therapy has only been used for relapsed and refractory patients, at which stage the endogenous T cells used to produce...
Main Authors: | Anthony M. Battram, Aina Oliver-Caldés, Maria Suárez-Lledó, Miquel Lozano, Miquel Bosch i Crespo, Núria Martínez-Cibrián, Joan Cid, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-09-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050122000894 |
Similar Items
-
IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
by: Anthony M. Battram, et al.
Published: (2021-07-01) -
sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01) -
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01) -
Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
by: Ikhwan Rinaldi, et al.
Published: (2022-07-01) -
Single VHH-directed BCMA CAR-NK cells for multiple myeloma
by: Quan Ren, et al.
Published: (2023-11-01)